Medpace: Bold Buybacks + Business Bounceback
Medpace repurchased about 10% of its stock in the first half of 2025
Contract research organization (CRO) Medpace had a remarkable day in the market following its second quarter earnings report, finishing 54.5% higher than its previous closing price.
I’ve written a lot about Medpace over the last 18 months or so - most recently highlighting a group meeting with management that I attended early last month.
After that meeti…